Key facts
- This page summarizes Michael G. Bator's Form 4 filing for Cytosorbents Corp (CTSO).
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 22 Jan 2025, 20:35.
Michael G. Bator - 17 Jan 2025 Form 4 Insider Report for Cytosorbents Corp (CTSO)
- Reporting relationship
- Director
- Issuer ticker
- CTSO
- Reported as of
- 17 Jan 2025
- Net transaction value
- +$15,879
- SEC form
- 4
- Accepted by SEC
- 22 Jan 2025, 20:35:13 UTC
- Prior SEC filing
- 04 Apr 2024
- Next SEC filing
- 04 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kathleen P. Bloch attorney-in-fact Michael G. Bator
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael G. Bator filed Form 4 for Cytosorbents Corp (CTSO) on 22 Jan 2025.
Change
- Previous filing in this sequence was filed on 04 Apr 2024.
- Current net transaction value: +$15,879.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CTSO
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $15,879
- Shares
- +15,879
- Change %
- +13%
- Price
- $1.00
- Shares after
- 141,273
- Date
- 17 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CTSO
transaction
Derivative
Subscription Rights (right to buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $0
- Shares
- -15,879
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 17 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,879
- Exercise price
- $1.00
- Footnotes
- F1
CTSO
transaction
Derivative
Series A Right Warrants
Other
- Transaction value
- Shares
- +15,879
- Change %
- Price
- Shares after
- 15,879
- Date
- 17 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,879
- Exercise price
- Footnotes
- F1, F3, F4
CTSO
transaction
Derivative
Series B Right Warrants
Other
- Transaction value
- Shares
- +15,879
- Change %
- Price
- Shares after
- 15,879
- Date
- 17 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,879
- Exercise price
- Footnotes
- F1, F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 15,879 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $15,879. The Rights Offering closed on January 10, 2025 (the "Closing Date").
Footnote F2
Includes (a) the following restricted stock units ("RSUs") which will vest upon a "Change of Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 3,300 RSUs granted on March 15, 2018, (ii) 6,000 RSUs granted on February 24, 2017, and (iii) 60,000 RSUs granted on June 7, 2016, and (b) 56,094 shares of Common Stock owned by the reporting person.
Footnote F3
The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.
Footnote F4
The Series A Right Warrants expire 45 calendar days following the Closing Date.
Footnote F5
The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.
Footnote F6
The Series B Right Warrants expire 90 calendar days following the Closing Date.